AD-214

Phase 1Biologic

AAdAlta Limited

AD-214 is one of 48 biologic programs targeting Interstitial Lung Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Interstitial Lung DiseaseActive, not recruiting

Interstitial Lung DiseasePhase 1

Active, not recruiting

Competition

Competitive Landscape

85 competitors in Interstitial Lung Disease

#DrugCompanyPhaseTrials

Cellcept

Roche

Phase 3

4 2

Rituxan

Roche

Phase 3

4 3

Cialis

Eli Lilly

Phase 3

1 4

Actemra

Roche

Phase 3

1 5

Benlysta

GGlaxo Dba Glaxosmithkline

Phase 3

1 6

Prograf

VVeloxis Pharmaceuticals

Phase 3

1 7

Jascayd

Boehringer Ingelheim

Phase 3

1 8

Orencia

Bristol-Myers Squibb

Phase 2

2 9

Elavil

AstraZeneca

Phase 2

1 10

Adempas

Bayer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Interstitial Lung Disease1 trial

Safety, Tolerability, PK and PD Study of AD-214 Administered to Healthy Volunteers and Patients With Interstitial Lung Disease or Chronic Kidney Disease

Completed·AAdAlta Limited·Phase 1·NCT05914909·8 enrolled

MPA1 trial

A Study to Compare PK, PD and Safety of the AD-214 and AD-2141

Completed·AAddpharma Inc.·Phase 1·NCT05062876·41 enrolled

Phase 11 trial

Phase 1 Safety, Tolerability, PK & PD Study of AD-214 Administered to Healthy Volunteers

Completed·AAdAlta Limited·Phase 1·NCT04415671·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for AD-214. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AD-214 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AD-214. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AdAlta Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: AAdAlta Limited

AD-214

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Interstitial Lung Disease1 trial

MPA1 trial

Phase 11 trial

References

Drug Info

Quick Facts

Related News